Looking Forward: Future Directions, Early-Line Trials, and the Prospect of Cure

Nooka draws parallels to the historical trajectory of daratumumab, which began in late-line settings before migrating to frontline quadruplets that now define standard of care. He predicts that bispecific antibodies will follow the same arc: moving earlier in treatment, integrating into combination regimens, and ultimately reshaping first-line therapy.

Joseph emphasizes equitable access, asserting that no patient should be denied a bispecific if they qualify. She reinforces the need for community oncologists to adopt these therapies, especially as their indications broaden.

Krishnamachary adds that although quadruplet regimens already deliver unprecedented remission depth and long PFS, high-risk patients—with del(17p) or extramedullary disease—remain an unmet need. He sees bispecifics as especially promising for these populations.

The conversation culminates in Jagannath’s bold assertion that myeloma is now a potentially curable disease. He cites long-term CAR T-cell outcomes showing MRD-negative, treatment-free remissions lasting over 5 years, and anticipates that BCMA bispecifics—especially when moved earlier and paired with other agents—will deliver similar results for a subset of patients.

The segment and program close with a clear message: bispecific antibodies are here to stay, and their expanding role will continue transforming myeloma care across both academic and community settings.